GenMark Diagnostics Stock Forecast, Price & News

GenMark Diagnostics' stock was trading at $5.42 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, GNMK stock has increased by 125.5% and is now trading at $12.22.
View which stocks have been most impacted by COVID-19.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GenMark Diagnostics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for GenMark Diagnostics.

GenMark Diagnostics is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for GenMark Diagnostics.

GenMark Diagnostics, Inc (NASDAQ:GNMK) released its quarterly earnings results on Wednesday, October, 28th. The medical equipment provider reported ($0.05) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.06) by $0.01. GenMark Diagnostics had a negative return on equity of 93.75% and a negative net margin of 26.51%.
View GenMark Diagnostics' earnings history.

GenMark Diagnostics issued an update on its FY 2020 After-Hours earnings guidance on Wednesday, October, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $165-168 million, compared to the consensus revenue estimate of $164.19 million.

6 brokers have issued 1-year price targets for GenMark Diagnostics' stock. Their forecasts range from $7.00 to $22.00. On average, they anticipate GenMark Diagnostics' stock price to reach $16.80 in the next twelve months. This suggests a possible upside of 37.5% from the stock's current price.
View analysts' price targets for GenMark Diagnostics.

Some companies that are related to GenMark Diagnostics include Inari Medical (NARI), Inspire Medical Systems (INSP), Merit Medical Systems (MMSI), Glaukos (GKOS), ShockWave Medical (SWAV), NuVasive (NUVA), Silk Road Medical (SILK), Cantel Medical (CMD), Axonics Modulation Technologies (AXNX), Inovio Pharmaceuticals (INO), AtriCure (ATRC), Cardiovascular Systems (CSII), Atrion (ATRI), OraSure Technologies (OSUR) and Luminex (LMNX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other GenMark Diagnostics investors own include Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Miragen Therapeutics (MGEN), Aeterna Zentaris (AEZS), BioNano Genomics (BNGO), CBL & Associates Properties (CBL) and Hallador Energy (HNRG).

GenMark Diagnostics trades on the NASDAQ under the ticker symbol "GNMK."

GenMark Diagnostics' stock is owned by a number of retail and institutional investors. Top institutional investors include Cowen Prime Services LLC (0.54%), Paradigm Capital Management Inc. NY (0.28%), M&G Investment Management Ltd. (0.11%), Envestnet Asset Management Inc. (0.03%), BNP Paribas Arbitrage SA (0.02%) and Dupont Capital Management Corp (0.02%). Company insiders that own GenMark Diagnostics stock include Alan Baer Maderazo, Brian Andrew Mitchell, Christine Shaw, Eric Stier, Hany Massarany, James B Mcnally, John Frederick Ek, Kevin C Oboyle, Michael Gleeson, Michael John Harkins, Michael Kagnoff, Sarah Hollis Winkler, Scott Alexander O'brien, Scott Mendel and Tyler Jensen.
View institutional ownership trends for GenMark Diagnostics.

GNMK stock was sold by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA, Cowen Prime Services LLC, Envestnet Asset Management Inc., OLD National Bancorp IN, and Dupont Capital Management Corp. Company insiders that have sold GenMark Diagnostics company stock in the last year include Alan Baer Maderazo, Brian Andrew Mitchell, Christine Shaw, Eric Stier, Hany Massarany, James B Mcnally, John Frederick Ek, Michael Gleeson, Michael John Harkins, Sarah Hollis Winkler, Scott Alexander O'brien, Scott Mendel, and Tyler Jensen.
View insider buying and selling activity for GenMark Diagnostics.

GNMK stock was purchased by a variety of institutional investors in the last quarter, including M&G Investment Management Ltd., Paradigm Capital Management Inc. NY, Nisa Investment Advisors LLC, and Harbor Investment Advisory LLC. Company insiders that have bought GenMark Diagnostics stock in the last two years include Kevin C Oboyle, and Michael Kagnoff.
View insider buying and selling activity for GenMark Diagnostics.

Shares of GNMK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GNMK stock can currently be purchased for approximately $12.22.

GenMark Diagnostics has a market capitalization of $868.49 million and generates $88.02 million in revenue each year. The medical equipment provider earns $-47,350,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis. GenMark Diagnostics employs 477 workers across the globe.

The official website for GenMark Diagnostics is www.genmarkdx.com.

GenMark Diagnostics' mailing address is 5964 LA PLACE COURT, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at 760-448-4300 or via email at [email protected]